**Table, Supplemental Digital Content 4. Randomized withdrawal period efficacy**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **LIN 290 µg – LIN 290 µg(N = 139)** | **LIN 290 µg – Placebo(N = 138)** | **Placebo – LIN 290 µg(N = 280)** |
| **Abdominal Score** |  |  |  |
| Week 12 change from baseline |  |  |  |
| n | 138 | 137 | 279 |
| Mean change from baseline (SD)  | −1.956 (2.186) | −2.525 (2.355)  | −1.422 (2.036) |
| Week 16 (RW Week 4) change from baseline  |  |  |  |
| na | 137  | 132  | 264 |
| Mean change from baseline (SD)  | −2.185 (2.341) | −2.087 (2.227) | −2.169 (2.242) |
| Week 16 (RW Week 4) change from Week 12  |  |  |  |
| na | 136 | 131 | 263 |
| Mean change from Week 12 | −0.22 (1.12) | 0.52 (1.84) | −0.76 (1.64)  |
| **CSBM frequency rate** |  |  |  |
| Week 12  |  |  |  |
| n | 139 | 137 | 279 |
| Mean change from baseline (SD)  | 2.211 (3.745)  | 2.620 (3.815) | 1.090 (2.080) |
| Week 16 (RW Week 4) |  |  |  |
| na | 138  | 134  | 268 |
| Mean change from baseline (SD)  | 1.777 (2.820)  | 1.489 (3.117)  | 2.134 (3.140) |

an = Number of patients with value at both Week 12 and baseline or both Week 16 and Week 12.
CSBM, complete spontaneous bowel movement; RW, randomized withdrawal; SD, standard deviation